🔗 Share this article World Health Organization Sounds Concern Over Acute Lack of Obesity Medications Fewer than one in 10 patients who could benefit from GLP-1 drugs like Wegovy can access them, states the World Health Organization as it publishes its inaugural advice on the therapies. With over a billion people worldwide currently classified as obese, it is urging more widespread and fairer access to GLP-1 medication. Per estimates, over two billion will be obese by 2030 if no action is taken. "Our new guidelines affirms that obesity is a long-term condition that can be managed with comprehensive and continuous care," remarked its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and supply-chain constraints are key hurdles to widespread availability to the jabs that can assist patients in reducing significant body mass, notes the agency. Weight-Loss Drug Supply Crisis Even in the present most optimistic case, the supply of these medications might only reach approximately 100 million people – under 10% of eligible patients, per the health organization. The recommendation calls on governments and firms to increase availability, by measures such as patent sharing. The intellectual property rights on semaglutide – the core component of the drug Wegovy – is set to lapse in a number of countries in 2026. How Weight-Loss Jabs Operate These medications imitate a body's own hormone to slow digestion, suppress the appetite and enhance the sense of being full so users reduce food intake. Patients typically start to lose weight after several weeks of starting on the once-weekly jabs. Research suggests patients may regain a significant portion within a year of halting the treatment, because their normal hunger return. To be above a healthy weight raises your risk for experiencing medical conditions, including type 2 diabetes, heart disease, brain attack, and some cancers. Obesity concerns people in every country and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
Fewer than one in 10 patients who could benefit from GLP-1 drugs like Wegovy can access them, states the World Health Organization as it publishes its inaugural advice on the therapies. With over a billion people worldwide currently classified as obese, it is urging more widespread and fairer access to GLP-1 medication. Per estimates, over two billion will be obese by 2030 if no action is taken. "Our new guidelines affirms that obesity is a long-term condition that can be managed with comprehensive and continuous care," remarked its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and supply-chain constraints are key hurdles to widespread availability to the jabs that can assist patients in reducing significant body mass, notes the agency. Weight-Loss Drug Supply Crisis Even in the present most optimistic case, the supply of these medications might only reach approximately 100 million people – under 10% of eligible patients, per the health organization. The recommendation calls on governments and firms to increase availability, by measures such as patent sharing. The intellectual property rights on semaglutide – the core component of the drug Wegovy – is set to lapse in a number of countries in 2026. How Weight-Loss Jabs Operate These medications imitate a body's own hormone to slow digestion, suppress the appetite and enhance the sense of being full so users reduce food intake. Patients typically start to lose weight after several weeks of starting on the once-weekly jabs. Research suggests patients may regain a significant portion within a year of halting the treatment, because their normal hunger return. To be above a healthy weight raises your risk for experiencing medical conditions, including type 2 diabetes, heart disease, brain attack, and some cancers. Obesity concerns people in every country and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.